Product Images Avonex Pen

This appears to be a graph showing the time to onset of sustained disability progression in patients with MS in Study 1. The graph compares the results of patients treated with AVONEX versus a placebo, with the percentage of patients progressing indicated on the y-axis and time in weeks on the x-axis. The text notes that there was a statistically significant difference between the two treatment groups (P=0.02).*

The text describes a figure (Figure 2) showing the percentage of patients with confirmed change in EDSS (Expanded Disability Status Scale) from study entry to the end of Study 1, represented by two groups: B AVONEX (sample size of 150) and Placebo (sample size of 136). The figure shows a statistical significance (P=0.006) between the two groups. The x-axis represents the confirmed change from baseline EDSS and the y-axis shows the percentage of patients. The figure is divided into "Better" and "Worse" outcomes. No further information is available in the text.*

This text describes a figure (Figure 3) that shows the time it takes for a second exacerbation to occur in two different groups (AVONEX and placebo) over a period of 36 months. The graph displays the number of subjects at risk in each group at various time points. Additionally, the data indicates that there is significant difference between AVONEX and placebo groups in terms of their rate ratio, with a p-value of 0.002 and rate ratio of 0.56.*

The text describes different components of a medical device named Avonex Pen. The components mentioned are a blue activation button with a tamper-evident cap, a Body Injector Shield with a grooved area, a Needle Cover, and a Foil.*

This is a glass syringe tip, which is a component typically used in laboratory and medical settings for dispensing and transferring small volumes of liquid substances. It is made of glass, which is a material known for its transparency, chemical resistance, and inertness, making it ideal for handling various types of fluids. The syringe tip is designed to fit and attach to the end of a syringe barrel, creating a precise and secure connection that can be used for accurate measuring and dosing.*

This is a short text with only one word and one phrase. The word is "Safety" and it is unclear what it refers to as there is no further context. The second part of the text is "Lock (visible)", which seems to indicate that there is a lock that is visible, possibly for safety purposes. However, without additional information, it is difficult to determine the exact meaning and purpose of this text.*

This text is not sufficient to generate a useful description.*

It appears that the text contains only fragmented words and characters. Hence, it is not readable and the description cannot be generated.*

This text refers to a medical instrument called "syringe tip". It is a small, pointed end of a syringe that enables medical practitioners to administer medication or draw blood.*

This text refers to a plunger, a tool used for unclogging toilets or drains by creating suction.*

Avonex Pen is a weekly dosage medication that contains interferon beta-1a which is administered via intramuscular injection. It is stored in the original carton at a temperature between 2°C to 8°C to protect it from light and should not be exposed to high temperatures or frozen. The injection is provided in a pre-filled autoinjector that may be stored at room temperature for a maximum of 7 days. The product contains natural rubber latex, which may cause allergies. The enclosed medication guide should be dispensed with each patient's prescription, and the prescribing information should be referred to for proper dosage information.*

Avonex Injection is a weekly dose pack treatment containing Interferon beta-1a. It is available in single-dose prefilled syringes for intramuscular injection, and can be stored at room temperature up to 25°C (77°F) for 7 days. Each syringe delivers 30 micrograms of interferon beta-1a and is preserved using natural rubber. The medication guide should be dispensed to each patient.*

This is a product description for the Avonex Pen, which is a medication used for treatment of multiple sclerosis. The product contains four pre-filled autoinjectors of interferon beta-1a, which need to be stored refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Each autoinjector includes a needle and plunger and is equipped with an adhesive bandage and alcohol wipe. Patients should be dispensed the enclosed medication guide. The NDC number for this product is 59627-333.04*

This text is a product description for Avonex, an interferon beta-1a injection. Avonex comes in a 30 mcg/0.5 mL single-dose prefilled syringe, is intended for intramuscular injection, and is administered once a week. Each Avonex administration dose pack contains one prefilled syringe and one injection needle, and there are four Avonex administration dose packs per container. The product does not contain preservatives or rubber latex. It should be stored refrigerated between 2°C and 8°C and protected from light. The medication guide should be dispensed to each patient. The manufacturer is Biogen Inc. The dosage instructions are included in the prescribing information.*

Avonex® is a drug that contains interferon beta-1a and is administered through intramuscular injection. It comes in a single-dose prefilled syringe with a 1 1/4" needle and must be stored in a refrigerator at a temperature of 2°C to 8°C (36°F to 46°F) to be protected from light. The package insert contains information on dosage and administration. The product contains natural rubber latex and can cause allergic reactions. The medication guide enclosed with the product must be given to the patient. The manufacturer of Avonex is Biogen Inc., located in Cambridge, MA. The product is only available with a prescription and has a National Drug Code of 59627-002-07.*